Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 6.26
CPIX's Cash-to-Debt is ranked higher than
59% of the 827 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.89 vs. CPIX: 6.26 )
Ranked among companies with meaningful Cash-to-Debt only.
CPIX' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.16  Med: 11.81 Max: No Debt
Current: 6.26
Equity-to-Asset 0.72
CPIX's Equity-to-Asset is ranked higher than
71% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. CPIX: 0.72 )
Ranked among companies with meaningful Equity-to-Asset only.
CPIX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.42  Med: 0.84 Max: 0.91
Current: 0.72
0.42
0.91
Debt-to-Equity 0.12
CPIX's Debt-to-Equity is ranked higher than
75% of the 535 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.30 vs. CPIX: 0.12 )
Ranked among companies with meaningful Debt-to-Equity only.
CPIX' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02  Med: 0.09 Max: 0.49
Current: 0.12
0.02
0.49
Debt-to-EBITDA -6.21
CPIX's Debt-to-EBITDA is ranked lower than
99.99% of the 503 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.74 vs. CPIX: -6.21 )
Ranked among companies with meaningful Debt-to-EBITDA only.
CPIX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -6.21  Med: 0.67 Max: 3.51
Current: -6.21
-6.21
3.51
Piotroski F-Score: 5
Altman Z-Score: 4.05
Beneish M-Score: -3.05
WACC vs ROIC
5.48%
-32.29%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -10.72
CPIX's Operating Margin % is ranked lower than
77% of the 781 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.94 vs. CPIX: -10.72 )
Ranked among companies with meaningful Operating Margin % only.
CPIX' s Operating Margin % Range Over the Past 10 Years
Min: -11.87  Med: 13.72 Max: 23.96
Current: -10.72
-11.87
23.96
Net Margin % -20.55
CPIX's Net Margin % is ranked lower than
79% of the 780 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.12 vs. CPIX: -20.55 )
Ranked among companies with meaningful Net Margin % only.
CPIX' s Net Margin % Range Over the Past 10 Years
Min: -20.55  Med: 6.84 Max: 14.41
Current: -20.55
-20.55
14.41
ROE % -11.26
CPIX's ROE % is ranked lower than
76% of the 803 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.08 vs. CPIX: -11.26 )
Ranked among companies with meaningful ROE % only.
CPIX' s ROE % Range Over the Past 10 Years
Min: -11.26  Med: 5.08 Max: 29.02
Current: -11.26
-11.26
29.02
ROA % -8.72
CPIX's ROA % is ranked lower than
76% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.77 vs. CPIX: -8.72 )
Ranked among companies with meaningful ROA % only.
CPIX' s ROA % Range Over the Past 10 Years
Min: -8.72  Med: 3.62 Max: 15.88
Current: -8.72
-8.72
15.88
ROC (Joel Greenblatt) % -198.52
CPIX's ROC (Joel Greenblatt) % is ranked lower than
82% of the 817 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.08 vs. CPIX: -198.52 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CPIX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -198.52  Med: 86.86 Max: 1721.07
Current: -198.52
-198.52
1721.07
3-Year Revenue Growth Rate 5.20
CPIX's 3-Year Revenue Growth Rate is ranked higher than
50% of the 674 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. CPIX: 5.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CPIX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -7.4  Med: 5.2 Max: 47.3
Current: 5.2
-7.4
47.3
3-Year EPS without NRI Growth Rate -18.30
CPIX's 3-Year EPS without NRI Growth Rate is ranked lower than
81% of the 632 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. CPIX: -18.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CPIX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -48.9  Med: -16.3 Max: 34.2
Current: -18.3
-48.9
34.2
GuruFocus has detected 4 Warning Signs with Cumberland Pharmaceuticals Inc CPIX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CPIX's 30-Y Financials

Financials (Next Earnings Date: 2018-03-07)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

CPIX Guru Trades in Q4 2016

Jim Simons 257,000 sh (+4.01%)
John Rogers 1,824,580 sh (-10.99%)
» More
Q1 2017

CPIX Guru Trades in Q1 2017

Jim Simons 270,240 sh (+5.15%)
John Rogers 1,393,125 sh (-23.65%)
» More
Q2 2017

CPIX Guru Trades in Q2 2017

Jim Simons 290,853 sh (+7.63%)
John Rogers 976,377 sh (-29.91%)
» More
Q3 2017

CPIX Guru Trades in Q3 2017

Jim Simons 316,005 sh (+8.65%)
John Rogers 887,144 sh (-9.14%)
» More
» Details

Insider Trades

Latest Guru Trades with CPIX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Rogers 2017-09-30 Reduce -9.14%0.01%$6.47 - $7.21 $ 7.7712%887,144
John Rogers 2017-06-30 Reduce -29.91%0.03%Premium Member Access $6.93 $ 7.7712%976,377
John Rogers 2017-06-30 Reduce -29.91%0.03%$5.56 - $7.07 $ 7.7718%976,377
John Rogers 2017-03-31 Reduce -23.65%0.03%$5.58 - $7.06 $ 7.7728%1,393,125
John Rogers 2016-12-31 Reduce -10.99%0.01%Premium Member Access $5.5 $ 7.7741%1,824,580
John Rogers 2016-12-31 Reduce -10.99%0.01%$4.7 - $5.72 $ 7.7749%1,824,580
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:TSXV:RX, ROCO:6539, HKSE:08049, XKRX:072020, NAS:DRRX, ROCO:6496, XKRX:900120, XKRX:131030, ROCO:4191, XKRX:001360, HKSE:01498, BOM:509079, BSP:BIOM3, TSE:4524, XPAR:IVA, XKRX:206650, MIL:PHN, PHS:EURO, TSXV:THCX, BOM:590006 » details
Traded in other countries:CBJ.Germany,
Headquarter Location:USA
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company. It is engaged in the acquisition, development and commercialization of branded prescription products. Its target markets are hospital acute care and gastroenterology.

Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company. It is engaged in the acquisition, development and commercialization of branded prescription products. Its target markets are hospital acute care and gastroenterology.

Ratios

vs
industry
vs
history
PB Ratio 1.90
CPIX's PB Ratio is ranked higher than
72% of the 798 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.86 vs. CPIX: 1.90 )
Ranked among companies with meaningful PB Ratio only.
CPIX' s PB Ratio Range Over the Past 10 Years
Min: 0.9  Med: 1.32 Max: 4.83
Current: 1.9
0.9
4.83
PS Ratio 3.22
CPIX's PS Ratio is ranked lower than
53% of the 756 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.79 vs. CPIX: 3.22 )
Ranked among companies with meaningful PS Ratio only.
CPIX' s PS Ratio Range Over the Past 10 Years
Min: 1.65  Med: 2.71 Max: 6.81
Current: 3.22
1.65
6.81
Price-to-Operating-Cash-Flow 168.91
CPIX's Price-to-Operating-Cash-Flow is ranked lower than
99.99% of the 290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.64 vs. CPIX: 168.91 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
CPIX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 11.3  Med: 26.88 Max: 7100
Current: 168.91
11.3
7100
EV-to-EBIT -20.68
CPIX's EV-to-EBIT is ranked lower than
99.99% of the 572 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.28 vs. CPIX: -20.68 )
Ranked among companies with meaningful EV-to-EBIT only.
CPIX' s EV-to-EBIT Range Over the Past 10 Years
Min: -377.8  Med: 7.9 Max: 993.7
Current: -20.68
-377.8
993.7
EV-to-EBITDA -62.15
CPIX's EV-to-EBITDA is ranked lower than
99.99% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.61 vs. CPIX: -62.15 )
Ranked among companies with meaningful EV-to-EBITDA only.
CPIX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -174.2  Med: 8.4 Max: 62.6
Current: -62.15
-174.2
62.6
EV-to-Revenue 2.08
CPIX's EV-to-Revenue is ranked higher than
67% of the 775 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.07 vs. CPIX: 2.08 )
Ranked among companies with meaningful EV-to-Revenue only.
CPIX' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.2  Med: 1.2 Max: 6.2
Current: 2.08
0.2
6.2
Shiller PE Ratio 83.40
CPIX's Shiller PE Ratio is ranked lower than
74% of the 204 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 36.18 vs. CPIX: 83.40 )
Ranked among companies with meaningful Shiller PE Ratio only.
CPIX' s Shiller PE Ratio Range Over the Past 10 Years
Min: 21.7  Med: 31 Max: 86.33
Current: 83.4
21.7
86.33
Current Ratio 4.18
CPIX's Current Ratio is ranked higher than
76% of the 738 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.53 vs. CPIX: 4.18 )
Ranked among companies with meaningful Current Ratio only.
CPIX' s Current Ratio Range Over the Past 10 Years
Min: 1.45  Med: 5.71 Max: 14.46
Current: 4.18
1.45
14.46
Quick Ratio 3.81
CPIX's Quick Ratio is ranked higher than
77% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.94 vs. CPIX: 3.81 )
Ranked among companies with meaningful Quick Ratio only.
CPIX' s Quick Ratio Range Over the Past 10 Years
Min: 1.38  Med: 5.29 Max: 13.46
Current: 3.81
1.38
13.46
Days Inventory 293.34
CPIX's Days Inventory is ranked lower than
93% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 120.98 vs. CPIX: 293.34 )
Ranked among companies with meaningful Days Inventory only.
CPIX' s Days Inventory Range Over the Past 10 Years
Min: 110.73  Med: 381.63 Max: 636.33
Current: 293.34
110.73
636.33
Days Sales Outstanding 68.16
CPIX's Days Sales Outstanding is ranked higher than
61% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.92 vs. CPIX: 68.16 )
Ranked among companies with meaningful Days Sales Outstanding only.
CPIX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 30.88  Med: 51.09 Max: 81.01
Current: 68.16
30.88
81.01
Days Payable 423.85
CPIX's Days Payable is ranked higher than
95% of the 619 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 68.69 vs. CPIX: 423.85 )
Ranked among companies with meaningful Days Payable only.
CPIX' s Days Payable Range Over the Past 10 Years
Min: 103.04  Med: 225.25 Max: 496.99
Current: 423.85
103.04
496.99

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 3.70
CPIX's 3-Year Average Share Buyback Ratio is ranked higher than
98% of the 522 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.80 vs. CPIX: 3.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CPIX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -7  Med: 2.1 Max: 5.1
Current: 3.7
-7
5.1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 4.98
CPIX's Price-to-Net-Cash is ranked higher than
82% of the 234 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.00 vs. CPIX: 4.98 )
Ranked among companies with meaningful Price-to-Net-Cash only.
CPIX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.37  Med: 2.29 Max: 6.72
Current: 4.98
1.37
6.72
Price-to-Net-Current-Asset-Value 3.02
CPIX's Price-to-Net-Current-Asset-Value is ranked higher than
84% of the 474 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.23 vs. CPIX: 3.02 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CPIX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.07  Med: 1.71 Max: 5.38
Current: 3.02
1.07
5.38
Price-to-Tangible-Book 2.84
CPIX's Price-to-Tangible-Book is ranked higher than
64% of the 735 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.49 vs. CPIX: 2.84 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CPIX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.04  Med: 1.65 Max: 5.21
Current: 2.84
1.04
5.21
Price-to-Intrinsic-Value-Projected-FCF 2.19
CPIX's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
59% of the 306 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.32 vs. CPIX: 2.19 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
CPIX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.7  Med: 1.1 Max: 2.19
Current: 2.19
0.7
2.19
Price-to-Median-PS-Value 1.19
CPIX's Price-to-Median-PS-Value is ranked lower than
59% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.04 vs. CPIX: 1.19 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CPIX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.63  Med: 1 Max: 2.39
Current: 1.19
0.63
2.39
Earnings Yield (Greenblatt) % -4.84
CPIX's Earnings Yield (Greenblatt) % is ranked lower than
77% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.23 vs. CPIX: -4.84 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CPIX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -18.2  Med: 5 Max: 79.2
Current: -4.84
-18.2
79.2
Forward Rate of Return (Yacktman) % -0.87
CPIX's Forward Rate of Return (Yacktman) % is ranked lower than
71% of the 397 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.07 vs. CPIX: -0.87 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
CPIX' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -0.87  Med: 3.9 Max: 18.9
Current: -0.87
-0.87
18.9

More Statistics

Revenue (TTM) (Mil) $38.58
EPS (TTM) $ -0.50
Beta0.53
Short Percentage of Float1.18%
52-Week Range $5.16 - 7.95
Shares Outstanding (Mil)15.75

Piotroski F-Score Details

Piotroski F-Score: 55
Positive ROAN
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyY
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}